Abstract:Abstract Background and Aims Lupus nephritis (LN) is one of the most severe manifestations of SLE; however, the Canadian patient experience remains understudied. This research investigated patient experiences and perspectives of 1) LN diagnosis; 2) living with LN; and 3) LN healthcare and treatment. Method Patients aged ≥18 years with biopsy-proven pure or mixed ISN/RPS Class III, IV, or V LN and fulfilling the ACR 1997 or SLICC 2012 Classification Criteria for SLE were purposefully recruited from a Canadian lupus cohort to participate in semi-structured in-depth interviews. These were conducted virtually and transcribed verbatim for subsequent thematic analysis using NVivo Qualitative Data Analysis Software. Results Thirty patients with LN were interviewed; 86.7% were female, mean (SD) age was 42.1 (16.4) years, mean (SD) age at SLE diagnosis was 29.8 (15.3) years (Table 1). Patients reported challenges seeking, receiving and adjusting to the LN diagnosis, and all described emotional impacts associated with diagnosis. Most patients had limited knowledge of LN prior to diagnosis, and this lack of understanding made it difficult to contextualise their illness (Figure 1). Patients reported both emotional wellbeing and physical health impacts associated with living with LN. While most have continued in paid employment, patients identified altered career aspirations, role changes, and the need for accommodations in the workplace. Patients also described modified leisure and social activities (Figure 1). While many identified supportive friends and family, a lack of nuanced understanding of their experiences by others was reported. LN was described as a factor in family planning considerations amongst those of childbearing age. Specifically, fear of changing LN medications and their reproductive side effects, fear of experiencing a flare while pregnant/when parenting, and concerns about passing on LN/other autoimmune conditions to their children emerged (Figure 1). Numerous aspects of LN management present challenges for patients, including visiting a range of healthcare providers, taking medication, monitoring diet, stress management and ensuring adequate rest. While many reported successful LN management with medication, others expressed concern with cost and side effects. The challenges associated with a lack of LN-specific information and resources were identified (Figure 1). Conclusion A lack of individual and public understanding of LN coupled with the uncertainties of diagnosis/living with LN create a substantial psychosocial burden as patients negotiate acceptable risk in the face of uncertainty (e.g., in family planning, treatment, paid employment, leisure). Results emphasize the need for wider LN awareness and will inform the development of LN-specific patient resources to increase understanding of LN and better support decision-making.

Real-world data in lupus nephritis: results from a European survey on renal function testing and burden of disease progression

THU0247 LRRN4: A NOVEL PROGNOSTIC BIOMARKER OF RENAL OUTCOME IN LUPUS NEPHRITIS PATIENTS

#4516 CLINICAL CHARACTERISTICS OF PATIENTS WITH LUPUS NEPHRITIS CLASS III–V: ANALYSIS OF INTERNATIONAL REAL-WORLD DATA

Systemic lupus erythematosus, lupus nephritis and end-stage renal disease: a pragmatic review mapping disease severity and progression

Evolution of diagnosis and treatment for lupus nephritis in Spain

Prediction of prognosis and renal outcome in lupus nephritis

Protecting the kidney in systemic lupus erythematosus: from diagnosis to therapy

Lupus nephritis: clinical presentations and outcomes in the 21st century

Attainment of EULAR/ERA-EDTA targets of therapy with current immunosuppressive regimens and adjustments in treatment: a multicentre, real-life observational study

Lupus Nephritis from Pathogenesis to New Therapies: An Update

Extrarenal symptoms associate with worse quality of life in patients enrolled in the AMP RA/SLE Lupus Nephritis Network

Clinical Features and Survival Analysis of Lupus Nephritis among Patients with Systemic Lupus Erythematosus: A Three-Decade-Long Retrospective Cohort Study

Risk of chronic kidney disease in 260 patients with lupus nephritis—analysis of a nationwide multicentre cohort with up to 35 years of follow-up

Early-stage predictors for treatment responses in patients with active lupus nephritis.

Results and prognosis of kidney transplantation in lupus nephritis: Experience of an Argentine center

Abstract 15 — Lupus Low Disease Activity State: An Underutilised Clinical Target that is Attainable and Protective against Lupus Nephritis Relapse

Specific in situ inflammatory states associate with progression to renal failure in lupus nephritis

#5479 EXPLORING CANADIAN PATIENT EXPERIENCES OF LIVING WITH LUPUS NEPHRITIS

A Comprehensive and Practical Approach to the Management of Lupus Nephritis in the Current Era

Urine proteomic signatures of histological class, activity, chronicity, and treatment response in lupus nephritis

Longitudinal patterns and predictors of response to standard-of-care therapy in lupus nephritis: data from the Accelerating Medicines Partnership Lupus Network